NASDAQ:RGNX REGENXBIO - RGNX Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding REGENXBIO Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $23.00 -0.09 (-0.39%) (As of 01/26/2023 04:14 PM ET) Add Compare Share Share Today's Range$22.64▼$23.1650-Day Range$21.33▼$24.5552-Week Range$18.69▼$35.73Volume175,285 shsAverage Volume304,505 shsMarket Capitalization$995.76 millionP/E Ratio14.84Dividend YieldN/APrice Target$41.43 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability REGENXBIO MarketRank™ ForecastAnalyst RatingModerate Buy2.67 Rating ScoreUpside/Downside81.3% Upside$41.43 Price TargetShort InterestBearish7.92% of Float Sold ShortDividend StrengthN/ASustainability-0.82Upright™ Environmental ScoreNews Sentiment0.25Based on 14 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($6.32) to ($3.27) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.36 out of 5 starsMedical Sector252nd out of 1,048 stocksBiological Products, Except Diagnostic Industry40th out of 168 stocks 3.3 Analyst's Opinion Consensus RatingREGENXBIO has received a consensus rating of Buy. The company's average rating score is 2.67, and is based on 4 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $41.43, REGENXBIO has a forecasted upside of 81.3% from its current price of $22.85.Amount of Analyst CoverageREGENXBIO has only been the subject of 3 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted7.92% of the float of REGENXBIO has been sold short.Short Interest Ratio / Days to CoverREGENXBIO has a short interest ratio ("days to cover") of 8.8.Change versus previous monthShort interest in REGENXBIO has recently increased by 9.68%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldREGENXBIO does not currently pay a dividend.Dividend GrowthREGENXBIO does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreREGENXBIO has received a 71.89% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is mostly driven by its "Clinical research services for genetic diseases", "Clinical research services for physiological diseases ", and "Basic medical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for REGENXBIO is -0.82. Previous Next 1.8 News and Social Media Coverage News SentimentREGENXBIO has a news sentiment score of 0.25. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.75 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 14 news articles for REGENXBIO this week, compared to 2 articles on an average week. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, REGENXBIO insiders have not sold or bought any company stock.Percentage Held by Insiders12.70% of the stock of REGENXBIO is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions80.21% of the stock of REGENXBIO is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for REGENXBIO are expected to grow in the coming year, from ($6.32) to ($3.27) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of REGENXBIO is 14.74, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 128.13.Price to Earnings Ratio vs. SectorThe P/E ratio of REGENXBIO is 14.74, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 93.66.Price to Book Value per Share RatioREGENXBIO has a P/B Ratio of 1.28. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About REGENXBIO (NASDAQ:RGNX) StockREGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's lead product candidate is RGX-314, which is in Phase III clinical trial for the treatment of wet age-related macular degeneration. It is also developing RGX-121 that is in Phase I/II clinical trial to treat mucopolysaccharidosis type II;RGX-111, which is in Phase I/II clinical trial for treating mucopolysaccharidosis type I;RGX-181 which is in pre clinic stage for the treatment of late-infantile neuronal ceroid lipofuscinosis type II disease;RGX-202, to treat Duchenne muscular dystrophy which is in phase I/II clinical trial; and RGX-381, to treat the ocular manifestations of CLN2 disease which is in preclinical stage. REGENXBIO Inc. also licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies; and has a collaboration and license agreement with Neurimmune AG to develop novel gene therapies. REGENXBIO Inc. was founded in 2008 and is headquartered in Rockville, Maryland.Read More Receive RGNX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for REGENXBIO and its competitors with MarketBeat's FREE daily newsletter. Email Address RGNX Stock News HeadlinesJanuary 26, 2023 | americanbankingnews.comSVB Leerink Cuts REGENXBIO (NASDAQ:RGNX) Price Target to $14.00January 26, 2023 | americanbankingnews.comREGENXBIO Inc. (NASDAQ:RGNX) to Post FY2024 Earnings of ($1.62) Per Share, SVB Leerink ForecastsJanuary 26, 2023 | PressReach (Ad)Stocks News AnnouncementDon't miss this update. Read the press release about Small Pharma.January 25, 2023 | americanbankingnews.comFY2022 EPS Estimates for REGENXBIO Inc. (NASDAQ:RGNX) Lowered by SVB LeerinkJanuary 25, 2023 | americanbankingnews.comREGENXBIO (NASDAQ:RGNX) Shares Down 3.7% Following Analyst DowngradeJanuary 23, 2023 | finance.yahoo.comREGENXBIO Announces Phase I/II Trial of RGX-202, a Novel Gene Therapy Candidate for Duchenne Muscular Dystrophy, is Active and Recruiting PatientsJanuary 9, 2023 | finance.yahoo.comREGENXBIO ANNOUNCES SENIOR LEADERSHIP PROMOTIONSJanuary 3, 2023 | finance.yahoo.comREGENXBIO Announces Presentation at the 41st Annual J.P. Morgan Healthcare ConferenceJanuary 26, 2023 | PressReach (Ad)Stocks News AnnouncementDon't miss this update. Read the press release about Small Pharma.December 21, 2022 | finance.yahoo.comREGENXBIO Reports Update on Advancement of Programs for CLN2 DiseaseDecember 8, 2022 | finance.yahoo.comREGENXBIO Announces Completion of Dosing in the Phase I/II Trial of RGX-111 for the Treatment of Severe MPS IDecember 3, 2022 | finance.yahoo.comREGENXBIO (NASDAQ:RGNX) adds US$71m to market cap in the past 7 days, though investors from three years ago are still down 46%November 3, 2022 | finance.yahoo.comRegenxbio (RGNX) Reports Q3 Loss, Lags Revenue EstimatesNovember 3, 2022 | finance.yahoo.comRegenxbio Says Diabetic Retinopathy Gene Therapy Shows Meaningful Improvements In Disease SeverityNovember 3, 2022 | finance.yahoo.comREGENXBIO Presents Positive Interim Data from and the Expansion of Phase II ALTITUDE® Trial of RGX-314 for the Treatment of Diabetic Retinopathy Using Suprachoroidal DeliveryNovember 3, 2022 | finance.yahoo.comREGENXBIO Reports Third Quarter 2022 Financial Results and Recent Operational HighlightsOctober 27, 2022 | finance.yahoo.comREGENXBIO to Host Conference Call on November 3 to Discuss Third Quarter 2022 Financial Results, Recent Operational Highlights and Interim Data from Phase II ALTITUDE® Trial of RGX-314 for the Treatment of Diabetic RetinopathyOctober 12, 2022 | finance.yahoo.comDeclining Stock and Decent Financials: Is The Market Wrong About REGENXBIO Inc. (NASDAQ:RGNX)?October 7, 2022 | benzinga.comDespite Solid Efficacy From Gene Therapy, This Analyst Cuts REGENXBIO's Price Target - Regenxbio (NASDAQ: - BenzingaOctober 4, 2022 | finance.yahoo.comDespite Solid Efficacy From Gene Therapy, This Analyst Cuts REGENXBIO's Price TargetOctober 4, 2022 | uk.investing.comAlphabet To $114? Plus This Analyst Predicts $145 For Disney By Benzinga - Investing.com UKOctober 4, 2022 | streetinsider.comRegenxbio (RGNX) Reports Additional Positive Interim Data from Trials of RGX-314 - StreetInsider.comOctober 3, 2022 | seekingalpha.comREGENXBIO says additional phase 2 data bolsters RGX-314 for wet macular degeneration - Seeking AlphaOctober 3, 2022 | benzinga.comREGENXBIO Announces Additional Interim Data From Trials Of RGX-314 For The Treatment Of Wet AMD - Regenxb - BenzingaSeptember 27, 2022 | benzinga.comREGENXBIO Announces Presentation at Chardan's 6th Annual Genetic Medicines Conference - Regenxbio (NASDAQ - BenzingaSeptember 27, 2022 | finance.yahoo.comREGENXBIO Announces Presentation at Chardan's 6th Annual Genetic Medicines ConferenceSeptember 26, 2022 | streetinsider.comREGENXBIO Announces Upcoming Presentations During the American Academy of Ophthalmology 2022 Annual Meeting - StreetInsider.comSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive RGNX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for REGENXBIO and its competitors with MarketBeat's FREE daily newsletter. Email Address RGNX Company Calendar Last Earnings11/03/2022Today1/26/2023Next Earnings (Estimated)3/07/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:RGNX CUSIPN/A CIK1590877 Webwww.regenxbio.com Phone(240) 552-8181FaxN/AEmployees372Year FoundedN/APrice Target and Rating Average Stock Price Forecast$41.43 High Stock Price Forecast$61.00 Low Stock Price Forecast$14.00 Forecasted Upside/Downside+80.1%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)$1.55 Trailing P/E Ratio14.84 Forward P/E RatioN/A P/E GrowthN/ANet Income$127.84 million Net Margins15.34% Pretax Margin18.12% Return on Equity12.22% Return on Assets8.14% Debt Debt-to-Equity RatioN/A Current Ratio3.53 Quick Ratio3.53 Sales & Book Value Annual Sales$470.35 million Price / Sales2.12 Cash Flow$3.27 per share Price / Cash Flow7.03 Book Value$17.87 per share Price / Book1.29Miscellaneous Outstanding Shares43,294,000Free Float37,796,000Market Cap$995.76 million OptionableOptionable Beta0.99 Key ExecutivesMr. Kenneth T. Mills (Age 48)Pres, CEO & Director Comp: $1.72MMr. Vittal K. Vasista (Age 55)Exec. VP & Chief Financial Officer Comp: $1.25MMr. Curran M. Simpson M.S. (Age 61)Exec. VP and Chief Operations & Technology Officer Comp: $924.95kDr. Olivier Danos Ph.D. (Age 65)Exec. VP & Chief Scientific Officer Comp: $842.08kMr. Patrick J. Christmas II (Age 52)J.D., Exec. VP & Chief Legal Officer Comp: $1.11MMs. Tricia TruehartVP of Investor Relations & Corp. CommunicationsMr. Andrew YostVP of Corp. Devel.Ms. Shiva G. FritschChief People OfficerDr. Laura A. Coruzzi J.D. (Age 70)Ph.D., Sr. VP of Intellectual Property Dr. Ram Palanki Pharm.D.Sr. VP of Commercial Strategy & OperationsMore ExecutivesKey CompetitorsValnevaNASDAQ:VALNSana BiotechnologyNASDAQ:SANANovavaxNASDAQ:NVAXAllogene TherapeuticsNASDAQ:ALLOInhibrxNASDAQ:INBXView All CompetitorsInsiders & InstitutionsBank Julius Baer & Co. Ltd ZurichSold 2,633 shares on 1/24/2023Ownership: 0.024%Allspring Global Investments Holdings LLCBought 5,164 shares on 1/23/2023Ownership: 0.030%Harbor Capital Advisors Inc.Sold 574 shares on 1/20/2023Ownership: 0.062%Stanley Laman Group Ltd.Bought 11,114 shares on 1/19/2023Ownership: 0.026%SummerHaven Investment Management LLCBought 519 shares on 1/18/2023Ownership: 0.062%View All Insider TransactionsView All Institutional Transactions RGNX Stock - Frequently Asked Questions Should I buy or sell REGENXBIO stock right now? 6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for REGENXBIO in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" RGNX shares. View RGNX analyst ratings or view top-rated stocks. What is REGENXBIO's stock price forecast for 2023? 6 equities research analysts have issued 1 year target prices for REGENXBIO's stock. Their RGNX share price forecasts range from $14.00 to $61.00. On average, they expect the company's stock price to reach $41.43 in the next year. This suggests a possible upside of 79.4% from the stock's current price. View analysts price targets for RGNX or view top-rated stocks among Wall Street analysts. How have RGNX shares performed in 2023? REGENXBIO's stock was trading at $22.68 on January 1st, 2023. Since then, RGNX stock has increased by 1.8% and is now trading at $23.09. View the best growth stocks for 2023 here. When is REGENXBIO's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 7th 2023. View our RGNX earnings forecast. How were REGENXBIO's earnings last quarter? REGENXBIO Inc. (NASDAQ:RGNX) issued its earnings results on Thursday, November, 3rd. The biotechnology company reported ($1.75) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.55) by $0.20. The biotechnology company earned $26.51 million during the quarter, compared to analyst estimates of $29.77 million. REGENXBIO had a net margin of 15.34% and a trailing twelve-month return on equity of 12.22%. What is Ken Mills' approval rating as REGENXBIO's CEO? 3 employees have rated REGENXBIO Chief Executive Officer Ken Mills on Glassdoor.com. Ken Mills has an approval rating of 68% among the company's employees. What other stocks do shareholders of REGENXBIO own? Based on aggregate information from My MarketBeat watchlists, some companies that other REGENXBIO investors own include AbbVie (ABBV), Micron Technology (MU), NVIDIA (NVDA), Voyager Therapeutics (VYGR), Amarin (AMRN), CRISPR Therapeutics (CRSP), Pfizer (PFE), QUALCOMM (QCOM), Gilead Sciences (GILD) and Block (SQ). What is REGENXBIO's stock symbol? REGENXBIO trades on the NASDAQ under the ticker symbol "RGNX." Who are REGENXBIO's major shareholders? REGENXBIO's stock is owned by many different retail and institutional investors. Top institutional shareholders include Hennion & Walsh Asset Management Inc. (0.24%), Harbor Capital Advisors Inc. (0.06%), SummerHaven Investment Management LLC (0.06%), Yousif Capital Management LLC (0.06%), Maryland State Retirement & Pension System (0.04%) and Allspring Global Investments Holdings LLC (0.03%). Insiders that own company stock include Allan M Fox, Curran Simpson, Kenneth T Mills, Kenneth T Mills, Patrick J Christmas, Steve Pakola, Vittal Vasista and WR Stephens, Iii 2012 Trust. View institutional ownership trends. How do I buy shares of REGENXBIO? Shares of RGNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is REGENXBIO's stock price today? One share of RGNX stock can currently be purchased for approximately $23.09. How much money does REGENXBIO make? REGENXBIO (NASDAQ:RGNX) has a market capitalization of $999.57 million and generates $470.35 million in revenue each year. The biotechnology company earns $127.84 million in net income (profit) each year or $1.55 on an earnings per share basis. How many employees does REGENXBIO have? The company employs 372 workers across the globe. How can I contact REGENXBIO? REGENXBIO's mailing address is 9600 BLACKWELL ROAD SUITE 210, ROCKVILLE MD, 20850. The official website for the company is www.regenxbio.com. The biotechnology company can be reached via phone at (240) 552-8181 or via email at ir@regenxbio.com. This page (NASDAQ:RGNX) was last updated on 1/26/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.